Aernoud Fiolet

180 Chapter 7 of 0.5mg twice daily and the COPS trial, which used 0.5mg twice daily during the first month, then 0.5mg daily thereafter. 25 Risk of bias assessment with the Risk- of-Bias 2 tool is summarized in Supplementary material, Table SA2. Table 2: Baseline characteristics of included trials Trial acronym Age Females Diabetes eGFR < 60 ml/ min/ 1.73m 2 History of ACS Antiplatelet therapy Statin therapy Beta-blocker therapy LoDoCo2 65·8±8·6 15·3% 18·3% 5·5% 84·4% 90·9% 94·0% 62·1% COPS 59·9±10·3 20·80% 19·0% N/A 100% 98·6% 98·9% 82·6% COLCOT 60·6±10·7 19·2% 20·2% N/A 100% 98·8% 99·0% 88·9% Deftereos 63·3 ±7·0 34·7% 100% 33·2% 31·1% NA NA NA LoDoCo 67±9·4 11·1% 30·3% NA 23·5% 93·4% 95·1% 66·5% ACS=acute coronary syndrome. eGFR=estimated glomerular filtration rate. Baseline characteristics of patients included in our analyses are summarized in Table 2. All 11 816 patients had established coronary disease, 5540 (46.9%) were enrolled within 30days of acute coronary syndrome, and 6276 (53.1%) were enrolled with chronic coronary disease. Patients had a median age of 63.3±9.6years and were mostlymale (84.0%). Medication at baseline was reported for 11 594 patients. Of these, 10 988 (94.8%) were taking single or dual antiplatelet therapy, 11 176 (96.4%) were taking statins and 8655 (74.7%) were taking beta- blockers. The majority (87.9%) had a history of acute coronary syndrome prior to randomization. Heart failure was uncommon as this was an exclusion criterion for most trials. The trial by Deftereos et al. 23 followed patients for 6months and the COPS trial for 1year, while the other trials followed patients for a median between 23 and 36months. 13,14,24,25 Permanent discontinuation of trial regimen was reported in 487 (8.2%) colchicine patients vs. 385 (6.8%) placebo patients. Proportions of patients lost to follow-up were low in both the colchicine (0.9%) and the control groups (1.0%). The trial by Deftereos et al. did not report on composite endpoints, myocardial infarction, or stroke.